Allos Therapeutics Incorporated

Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. Since 1994, we have been committed to improving the health and well being of people with life-limiting diseases. Headquartered in Westminster, Colorado, a suburb of Denver, Allos is strategically positioned to become a leading oncology-focused biopharmaceutical company. Allos' lead product candidate, RSR13 (efaproxiral), is an innovative radiation sensitizer being developed initially to treat brain metastases (cancer that has spread to the brain from another part of the body). RSR13 is also being evaluated as a radiosensitizing agent in patients with glioblastoma multiforme and non-small cell lung cancer who are receiving radiation therapy. Allos owns the worldwide marketing rights and has filed patents in the major industrialized countries of the world.

Contact Details: 11080 CirclePoint Road, Suite 200 Westminster 80020 United States of America Tel: 303 426 6262 Fax: 303 426 4731 Email: corpcomm@allos.com WWW: www.allos.com/

Recent Publications by Allos Therapeutics Incorporated:
Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy. RSR13 binds to hemoglobin (Hb), reduces oxygen (O2) binding affinity, and...	3rd December, 2003	Allos Therapeutics, Inc., 11080 CirclePoint Road, Suite 200, Westminster,	Adv Exp Med Biol. 2003;530:249-59.

BioNews Results for Allos Therapeutics Incorporated:
Allos Therapeutics Announces New Data on Folotyn to be Presented at the American Society of Hematology Meeting	Pharma Live:  Nov 12 2009 12:05AM Matching: allos therapeutics
Allos Therapeutics awards NCCN a grant to evaluate pralatrexate	News-Medical.Net:  Nov 11 2009 7:00AM Matching: allos therapeutics
Allos Therapeutics to Present at Upcoming Conferences in November	SmartBrief:  Nov 11 2009 1:57AM Matching: allos therapeutics
Allos Therapeutics, Inc. (ALTH) Announces New Data on FOLOTYN(TM) to be Presented at the American Society of H	BioSpace:  Nov 11 2009 7:45PM Matching: allos therapeutics
Allos Therapeutics Announces New Data on FOLOTYN to be Presented at the American Society of Hematology Meeting	Yahoo! Canada:  Nov 11 2009 3:11PM Matching: allos therapeutics
Promote your company here: BioNewsCast - Press Release Distribution	→View more Allos Therapeutics Incorporated news.

Allos Therapeutics Incorporated Clinical Trials:
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-Small Cell Lung Cancer

Allos Therapeutics Incorporated Patents:
US Patent No.	Title
7097825	Methods and reagents to acquire MRI signals and images
6894185	Substituted chiral allosteric hemoglobin modifiers
6534501	Allosteric inhibitors of pyruvate kinase
5677330	Medical uses of allosteric hemoglobin modifier compounds in patient care
5525630	Treatment for carbon monoxide poisoning
→View more Allos Therapeutics Incorporated patents.

Allos Therapeutics Incorporated (ALTH) Financial information Links from Barchart
ALTH Quote from from Barchart.com
ALTH Chart from from Barchart.com
ALTH Profile from from Barchart.com
ALTH Opinion from from Barchart.com
→View more Allos Therapeutics Incorporated finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 458 times since April 2007, the link to the organisation's website has been followed 68 times

Search for more companies in Westminster

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Allos Therapeutics Incorporated